Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL ) 4.000 -0.480 (-10.71%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vigil Neuroscience, Inc. - Common Stock < Previous 1 2 3 4 5 Next > Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE November 16, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update November 07, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience's Focus On Neurodegenerative Diseases: Analyst Says Pipeline Offers Upside Opportunities To Valuation October 18, 2023 JMP Securities has initiated coverage on Vigil Neuroscience Inc (NASDAQ: VIGL), noting the company's focus on neurodegenerative diseases. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023 October 18, 2023 Via Benzinga Vigil Neuroscience: Q1 Earnings Insights May 10, 2023 Via Benzinga What 4 Analyst Ratings Have To Say About Vigil Neuroscience April 03, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session October 17, 2023 Via Benzinga Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease October 17, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session October 06, 2023 Via Benzinga Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session October 06, 2023 Gainers Via Benzinga Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit October 05, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP September 26, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session September 21, 2023 Via Benzinga Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting September 11, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program September 08, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference September 08, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Stocks That Hit 52-Week Lows On Wednesday August 09, 2023 On Wednesday, 155 companies set new 52-week lows. Via Benzinga Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update August 08, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Stocks That Hit 52-Week Lows On Thursday September 07, 2023 On Thursday, 283 companies set new 52-week lows. Via Benzinga Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer August 07, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus July 13, 2023 Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. Via MarketBeat Topics Retirement Exposures Pension Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference June 01, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update May 10, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors May 09, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) May 08, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 March 31, 2023 Via Benzinga Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101 March 30, 2023 Company remains on track to report interim data from Phase 2 trial in the second half of 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 27, 2023 Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider. Via Benzinga BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday March 27, 2023 U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. Via Benzinga Vigil Neuroscience to Present at Stifel 2023 CNS Days March 22, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.